NCT01031927

N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)

Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: China Medical University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Several lines of evidence implicate glutamatergic dysfunction in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine, also known as N-methylglycine, is an endogenous antagonist of glycine transporter-I (GlyT-I), which potentiates glycine's action at the glycine site of N-methyl-D-aspartate (NMDA) receptors. In this 10-week open-label trial, we examined the efficacy and safety of sarcosine treatment in OCD patients.

Conditions

• Obsessive Compulsive Disorder

Interventions

Type	Name	Description
DRUG	N-methyl glycine	staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day

Timeline

• Start date: 2007-06-01
• Primary completion: 2009-02-01
• First posted: 2009-12-15
• Last updated: 2009-12-29

Locations

1 site across 1 country: Taiwan